My guess is 2/3 of the reduction is due to patent expirations and 1/3 to general downsizing and increased emphasis on specialty rather then primary-care drugs.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”